Search company, investor...



Unattributed - V | Alive

Total Raised


Last Raised

$130K | 1 yr ago



About MedWave

MedWave offers a platform that allows healthcare providers to manage all aspects of clinical and facility operations, improving the quality of care and financial performance in complex hospital and outpatient environments.

Headquarters Location

6800 Palm Avenue Suite D

Sebastopol, California, 95472,

United States


Missing: MedWave's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: MedWave's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing MedWave

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MedWave is included in 2 Expert Collections, including Digital Health.


Digital Health

12,620 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

2,337 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.

Latest MedWave News

Characteristics of Living Systematic Review for COVID-19

Aug 4, 2022

. 13. A systematic review that is ``rapid’’ and ``living’’: a specific answer to the COVID-19 pandemic. J Clin Epidemiol. 2021;138:194–198. doi:10.1016/j.jclinepi.2021.05.025 14. Iannizzi C, Dorando E, Burns J, et al. Methodological challenges for living systematic reviews conducted during the COVID-19 pandemic: a concept paper. J Clin Epidemiol. 2022;141:82–89. doi:10.1016/j.jclinepi.2021.09.013 15. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):b2535. doi:10.1136/bmj.b2535 16. Allotey J, Chatterjee S, Kew T, et al. SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis. BMJ. 2022;376:e067696. doi:10.1136/bmj-2021-067696 17. Allotey J, Fernandez S, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi:10.1136/bmj.m3320 18. Amer YS, Titi MA, Godah MW, et al. International alliance and AGREE-ment of 71 clinical practice guidelines on the management of critical care patients with COVID-19: a living systematic review. J Clin Epidemiol. 2022;142:333–370. doi:10.1016/j.jclinepi.2021.11.010 19. Amorim Dos Santos J, Normando AGC, Carvalho da Silva RL, et al. Oral manifestations in patients with COVID-19: a 6-month update. J Dent Res. 2021;100(12):1321–1329. doi:10.1177/00220345211029637 20. Ansems K, Grundeis F, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;8(8):Cd014962. doi:10.1002/14651858.Cd014962 21. Asiimwe IG, Pushpakom S, Turner RM, et al. Cardiovascular drugs and COVID-19 clinical outcomes: a living systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(12):4534–4545. doi:10.1111/bcp.14927 22. Baladia E, Pizarro AB, Ortiz-Muñoz L, et al. Vitamin C for COVID-19: a living systematic review. Medwave. 2020;20(6):e7978. doi:10.5867/medwave.2020.06.7978 23. Bartoszko JJ, Siemieniuk RAC, Kum E, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021;373(949). doi:10.1136/bmj.n949 24. Bell V, Wade D. Mental health of clinical staff working in high-risk epidemic and pandemic health emergencies a rapid review of the evidence and living meta-analysis. Soc Psychiatry Psychiatr Epidemiol. 2021;56(1):1–11. doi:10.1007/s00127-020-01990-x 25. Bonardi O, Wang Y, Li K, et al. Effects of COVID-19 mental health interventions among children, adolescents, and adults not quarantined or undergoing treatment due to COVID-19 infection: a systematic review of randomised controlled trials. The Canadian Journal of Psychiatry. 2022;67(5):336–350. doi:10.1177/07067437211070648 26. Brümmer LE, Katzenschlager S, Gaeddert M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis. PLoS Med. 2021;18(8):e1003735. doi:10.1371/journal.pmed.1003735 27. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med. 2020;17(9):e1003346. doi:10.1371/journal.pmed.1003346 28. Bwire GM, Njiro BJ, Mwakawanga DL, et al. Possible vertical transmission and antibodies against SARS-CoV-2 among infants born to mothers with COVID-19: a living systematic review. J Med Virol. 2021;93(3):1361–1369. doi:10.1002/jmv.26622 29. Cares-Marambio K, Montenegro-Jiménez Y, Torres-Castro R, et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Chron Respir Dis. 2021;18:14799731211002240. doi:10.1177/14799731211002240 30. Centeno‐Tablante E, Medina‐Rivera M, Finkelstein JL, et al. Transmission of SARS-CoV-2 through breast milk and breastfeeding: a living systematic review. Ann N Y Acad Sci. 2021;1484(1):32–54. doi:10.1111/nyas.14477 31. Ceravolo MG, Andrenelli E, Arienti C, et al. Rehabilitation and COVID-19: rapid living systematic review by cochrane rehabilitation field - third edition. Eur J Phys Rehabil Med. 2021;57(5):850–857. doi:10.23736/s1973-9087.21.07301-9 32. Davidson M, Menon S, Chaimani A, et al. Interleukin-1 blocking agents for treating COVID-19. Cochrane Database Syst Rev. 2022;1(1):Cd015308. doi:10.1002/14651858.Cd015308 33. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020;6(6):Cd013652. doi:10.1002/14651858.Cd013652 34. Dong F, Liu H-L, Dai N, et al. A living systematic review of the psychological problems in people suffering from COVID-19. J Affect Disord. 2021;292:172–188. doi:10.1016/j.jad.2021.05.060 35. Dzinamarira T, Nkambule SJ, Hlongwa M, et al. Risk factors for COVID-19 infection among healthcare workers. A first report from a living systematic review and meta-analysis. Saf Health Work. 2022. doi:10.1016/ 36. Elvidge J, Summerfield A, Nicholls D, et al. Diagnostics and treatments of COVID-19: a living systematic review of economic evaluations. Value Health. 2022;25(5):773–784. doi:10.1016/j.jval.2022.01.001 37. Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;3(3):Cd013881. doi:10.1002/14651858.Cd013881 38. Gómez-Ochoa SA, Franco OH, Rojas LZ, et al. COVID-19 in health-care workers: a living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. Am J Epidemiol. 2021;190(1):161–175. doi:10.1093/aje/kwaa191 39. Griesel M, Wagner C, Mikolajewska A, et al. Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2022;3(3):Cd015125. doi:10.1002/14651858.Cd015125 40. Harder T, Koch J, Vygen-Bonnet S, et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Euro Surv. 2021;26(28). doi:10.2807/1560-7917.Es.2021.26.28.2100563 41. Harder T, Külper-Schiek W, Reda S, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis. Euro Surv. 2021;26(41). doi:10.2807/1560-7917.Es.2021.26.41.2100920 42. Helfand M, Fiordalisi C, Wiedrick J, et al. Risk for reinfection after SARS-CoV-2: a living, rapid review for American College of physicians practice points on the role of the antibody response in conferring immunity following SARS-CoV-2 infection. Ann Intern Med. 2022. doi:10.7326/m21-4245 43. Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med. 2020;173(4):287–296. doi:10.7326/m20-2496 44. Hussain S, Riad A, Singh A, et al. Global prevalence of COVID-19-associated mucormycosis (CAM): living systematic review and meta-analysis. J Fungi. 2021;7(11). doi:10.3390/jof7110985 45. John A, Eyles E, Webb RT, et al. The impact of the COVID-19 pandemic on self-harm and suicidal behaviour: update of living systematic review. F1000Res. 2020;9:1097. doi:10.12688/f1000research.25522.2 46. Juul S, Nielsen EE, Feinberg J, et al. Interventions for treatment of COVID-19: a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS Med. 2020;17(9):e1003293. doi:10.1371/journal.pmed.1003293 47. Kirkham AM, Monaghan M, Bailey AJM, et al. Mesenchymal stem/stromal cell-based therapies for COVID-19: first iteration of a living systematic review and meta-analysis: mSCs and COVID-19. Cytotherapy. 2022. doi:10.1016/j.jcyt.2021.12.001 48. Korang SK, von Rohden E, Veroniki AA, et al. Vaccines to prevent COVID-19: a living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. PLoS One. 2022;17(1):e0260733. doi:10.1371/journal.pone.0260733 49. Kreuzberger N, Hirsch C, Chai KL, et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021;9(9):Cd013825. doi:10.1002/14651858.CD013825 50. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622–1629. doi:10.1016/j.cmi.2020.07.016 51. Mackey K, King VJ, Gurley S, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med. 2020;173(3):195–203. doi:10.7326/m20-1515 52. Maguire BJ, McLean ARD, Rashan S, et al. Baseline results of a living systematic review for COVID-19 clinical trial registrations. Wellcome Open Res. 2020;5:116. doi:10.12688/wellcomeopenres.15933.1 53. Melo AKG, Milby KM, Caparroz A, et al. Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: a living systematic review and meta-analysis. PLoS One. 2021;16(6):e0253894. doi:10.1371/journal.pone.0253894 54. Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Global Health. 2021;6(9). doi:10.1136/bmjgh-2021-005427 55. Mikolajewska A, Fischer AL, Piechotta V, et al. Colchicine for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;10(10):Cd015045. doi:10.1002/14651858.Cd015045 56. O’Byrne L, Webster KE, MacKeith S, et al. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev. 2021;7(7):Cd013876. doi:10.1002/14651858.CD013876 57. Qiu X, Nergiz AI, Maraolo AE, et al. The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission-a living systematic review. Clin Microbiol Infect. 2021;27(4):511–519. doi:10.1016/j.cmi.2021.01.011 58. Rada G, Corbalán J, Rojas P. Cell-based therapies for COVID-19: a living, systematic review. Medwave. 2020;20(11):e8079. doi:10.5867/medwave.2020.11.8078 59. Rocha APD, Atallah ÁN, Pinto A, et al. COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review. Sao Paulo Med J. 2020;138(6):515–520. doi:10.1590/1516-3180.2020.0421.R2.10092020 60. Salameh JP, Leeflang MM, Hooft L, et al. Thoracic imaging tests for the diagnosis of COVID-19. Cochrane Database Syst Rev. 2020;9:Cd013639. doi:10.1002/14651858.CD013639 61. Schlesinger S, Neuenschwander M, Lang A, et al. Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis. Diabetologia. 2021;64(7):1480–1491. doi:10.1007/s00125-021-05458-8 62. Schünemann HJ, Khabsa J, Solo K, et al. Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19: a living systematic review of multiple streams of evidence. Ann Intern Med. 2020;173(3):204–216. doi:10.7326/m20-2306 63. Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. 2021;374:n2231. doi:10.1136/bmj.n2231 64. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980. 65. Silveira FM, Mello ALR, da Silva Fonseca L, et al. Morphological and tissue-based molecular characterization of oral lesions in patients with COVID-19: a living systematic review. Arch Oral Biol. 2022;136:105374. doi:10.1016/j.archoralbio.2022.105374 66. Soto-Cámara R, García-Santa-Basilia N, Onrubia-Baticón H, et al. Psychological Impact of the COVID-19 pandemic on out-of-hospital health professionals: a living systematic review. J Clin Med. 2021;10(23). doi:10.3390/jcm10235578 67. Stroehlein JK, Wallqvist J, Iannizzi C, et al. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;5(5):Cd015043. doi:10.1002/14651858.Cd015043 68. Tleyjeh IM, Kashour Z, Riaz M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update. Clin Microbiol Infect. 2021;27(8):1076–1082. doi:10.1016/j.cmi.2021.04.019 69. Valk SJ, Piechotta V, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev. 2020;5(5):Cd013600. doi:10.1002/14651858.Cd013600 70. Verdejo C, Vergara-Merino L, Meza N, et al. Macrolides for the treatment of COVID-19: a living, systematic review. Medwave. 2020;20(11):e8074. doi:10.5867/medwave.2020.11.8073 71. Verdugo-Paiva F, Acuña MP, Solá I, et al. Remdesivir for the treatment of COVID-19: a living systematic review. Medwave. 2020;20(11):e8080. doi:10.5867/medwave.2020.11.8080 72. Verdugo-Paiva F, Izcovich A, Ragusa M, et al. Lopinavir-ritonavir for COVID-19: a living systematic review. Medwave. 2020;20(6):e7967. doi:10.5867/medwave.2020.06.7966 73. Wagner C, Griesel M, Mikolajewska A, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;8(8):Cd014963. doi:10.1002/14651858.Cd014963 74. Wilt TJ, Kaka AS, MacDonald R, et al. Remdesivir for adults with COVID-19: a living systematic review for American College of physicians practice points. Ann Intern Med. 2021;174(2):209–220. doi:10.7326/m20-5752 75. Webster KE, O'Byrne L, MacKeith S, et al. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev. 2021;7(7):Cd013877. doi:10.1002/14651858.CD013877.pub2 76. Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ. 2020;369:m1328. doi:10.1136/bmj.m1328 77. Xu W, Li X, Dong Y, et al. SARS-CoV-2 transmission in schools: an updated living systematic review. J Glob Health. 2021;11:10004. doi:10.7189/jogh.11.10004 78. Yang J, D’Souza R, Kharrat A, et al. Coronavirus disease 2019 pandemic and pregnancy and neonatal outcomes in general population: a living systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2022;101(1):7–24. doi:10.1111/aogs.14277 79. Zhang X, Shang L, Fan G, et al. The efficacy and safety of janus kinase inhibitors for patients with COVID-19: a living systematic review and meta-analysis. Front Med. 2021;8:800492. doi:10.3389/fmed.2021.800492 80. Dotto L, Kinalski MA, Machado PS, et al. The mass production of systematic reviews about COVID-19: an analysis of PROSPERO records. J Evid Based Med. 2021;14(1):56–64. doi:10.1111/jebm.12426 81. Sideri S, Papageorgiou SN, Eliades T. Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality. J Clin Epidemiol. 2018;100:103–110. doi:10.1016/j.jclinepi.2018.01.003 82. Chien PF, Khan KS, Siassakos D. Registration of systematic reviews: PROSPERO. BJOG. 2012;119(8):903–905. doi:10.1111/j.1471-0528.2011.03242.x 83. Ge L, Tian JH, Li YN, et al. Association between prospective registration and overall reporting and methodological quality of systematic reviews: a meta-epidemiological study. J Clin Epidemiol. 2018;93:45–55. doi:10.1016/j.jclinepi.2017.10.012 84. Brierley L, Nanni F, Polka JK, et al. Tracking changes between preprint posting and journal publication during a pandemic. PLoS Biol. 2022;20(2):e3001285. doi:10.1371/journal.pbio.3001285 85. Rawlinson C, Bloom T. New preprint server for medical research. BMJ. 2019;365:l2301. doi:10.1136/bmj.l2301 86. Lansky A, Wethington HR. Living systematic reviews and other approaches for updating evidence. Am J Public Health. 2020;110(11):1687–1688. doi:10.2105/ajph.2020.305920 87. Thomas J, Noel-Storr A, Marshall I, et al. Living systematic reviews: 2. Combining human and machine effort. J Clin Epidemiol. 2017;91:31–37. doi:10.1016/j.jclinepi.2017.08.011 88. Chou R, Dana T, Shetty KD. Testing a machine learning tool for facilitating living systematic reviews of chronic pain treatments. In: AHRQ Methods for Effective Health Care. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020. 89. Butcher R, Sampson M, Couban RJ, et al. The currency and completeness of specialized databases of COVID-19 publications. J Clin Epidemiol. 2022;147:52–59. doi:10.1016/j.jclinepi.2022.03.006 90. Rada G, Pérez D, Araya-Quintanilla F, et al. Epistemonikos: a comprehensive database of systematic reviews for health decision-making. BMC Med Res Methodol. 2020;20(1):286. doi:10.1186/s12874-020-01157-x 91. Pierre O, Riveros C, Charpy S, et al. Secondary electronic sources demonstrated very good sensitivity for identifying studies evaluating interventions for COVID-19. J Clin Epidemiol. 2021;141:46–53. doi:10.1016/j.jclinepi.2021.09.022 92. Créquit P, Martin-Montoya T, Attiche N, et al. Living network meta-analysis was feasible when considering the pace of evidence generation. J Clin Epidemiol. 2019;108:10–16. doi:10.1016/j.jclinepi.2018.12.008 93. Tercero-Hidalgo JR, Khan KS, Bueno-Cavanillas A, et al. Artificial intelligence in COVID-19 evidence syntheses was underutilized, but impactful: a methodological study. J Clin Epidemiol. 2022;148:124–134. doi:10.1016/j.jclinepi.2022.04.027 94. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71–n71. doi:10.1136/bmj.n71 95. Whiting P, Savović J, Higgins JP, et al. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225–234. doi:10.1016/j.jclinepi.2015.06.005 96. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. doi:10.1136/bmj.j4008 This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License .By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms .

MedWave Frequently Asked Questions (FAQ)

  • Where is MedWave's headquarters?

    MedWave's headquarters is located at 6800 Palm Avenue, Sebastopol.

  • What is MedWave's latest funding round?

    MedWave's latest funding round is Unattributed - V.

  • How much did MedWave raise?

    MedWave raised a total of $7.33M.

  • Who are the investors of MedWave?

    Investors of MedWave include Paycheck Protection Program.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.